.svg)
.svg)
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg){kind=icon}
.svg){kind=icon}
Publication date: September 10, 2025
Qiagen N.V. is a leading global provider of biotechnology and molecular diagnostic solutions. The company develops technologies and products used to isolate and analyze DNA, RNA and proteins, and plays an important role in medical diagnostics and life sciences. In this article, you can read all about Qiagen stock: share price, performance, business strategy and expectations for 2025. Would you like to receive weekly updates on European stocks? Then subscribe to our newsletter here and stay informed.
.webp)
- Year of establishment: 1984
- Year added to the DAX 40: 2021
-Highest price ever: €64.42, July 2000
-Average trading volume: 1.44 million shares per day
- Price performance over the past 12 months: -3,07%
Introduction about the company
Qiagen N.V. was founded in 1984 in Düsseldorf and today is headquartered in Venlo, the Netherlands. The company provides technologies for laboratories, hospitals and pharmaceutical companies worldwide. Best known for its molecular diagnostic tests, Qiagen is used for infectious diseases, oncology and genetic research, among other things. During the corona pandemic, Qiagen was in the spotlight for its test kits, but the company remains an important player even after that due to its broad portfolio and global customer base.
Key figures & achievements
In 2024, Qiagen had revenues of about €2 billion and net profits of about €140 million. Despite these solid results, the stock experienced a decline of over 3% over the past 12 months. Its market capitalization in July 2025 was approximately €9.6 billion, placing Qiagen among the smaller players within the DAX 40.
History & development
Qiagen began in 1984 as a small supplier of nucleic acid isolation products. In the 1990s, the company greatly expanded its business and gained international prominence. In 2000, the stock reached a record price during the biotech boom, followed by a long period of consolidation. Its inclusion in the DAX 40 in 2021 confirmed Qiagen's role as an established player within the European biotech sector.
Sector & competition
Qiagen operates in the biotechnology and diagnostics sector, a market driven by innovation, high research costs and increasing demand for precision medicine. Key competitors include Illumina, Thermo Fisher Scientific and Roche Diagnostics. The sector benefits from structural trends such as an aging population, preventive health care and personalized therapies, while being sensitive to price pressures and rapid technological developments.
Influence of Qiagen on the DAX 40
With a weighting of 0.54% (measured in July 2025) within the DAX-40, Qiagen occupies a relatively small but stable position in the index. Movements in the share price, therefore, have a limited impact on the overall performance of the DAX, but do give investors insight into trends within the biotech and diagnostics sector. The stock price responds primarily to research results, product launches and regulatory approvals. View the composition of the DAX 40 and the weighting of all companies in the DAX 40 here.
Investment analysis & outlook
Qiagen shares experienced a modest decline of over 3% over the past 12 months, lagging behind the broader DAX. However, the chart shows Qiagen's striking share price performance: while many companies were still struggling with the aftermath of the corona pandemic in 2021, Qiagen actually benefited from global demand for test kits and diagnostic solutions. This explains the stock's sharp rise during that period, which is clearly distinct from the pattern of the index.
Since 2022, the stock has moved sideways and experienced pressure from normalizing test volumes and increasing competition in the diagnostics sector. Whereas the DAX managed to continue rising sharply from then on, Qiagen remained stuck in a wide range. The recovery in 2025 shows that investors see renewed confidence in the broader product portfolio, such as oncology diagnostics and genetic testing.
Looking ahead, Qiagen's focus is on diversification beyond pandemic-related products. Successful launches of new diagnostic applications and expansion into growth markets such as Asia and North America are crucial to regaining structural growth. For investors who believe in the long-term potential of biotechnology and precision medicine, Qiagen remains an interesting but also volatile player within the DAX 40.
News & updates
In 2025, Qiagen announced a collaboration with a major U.S. pharmaceutical company to develop new diagnostic tests for personalized therapies. In addition, the company is investing heavily in digitization and automated laboratory solutions, further improving efficiency for customers. Despite the recent share price pressure, the strategy remains focused on sustainable growth through innovation and global expansion.
With this long-term strategy, Qiagen continues to position itself as an innovative player within the global molecular diagnostics and biotechnology market. More information about the company can be found at: www.qiagen.com
Disclaimer: Investing involves risk. Our analysts are not financial advisors. Always consult an advisor when making financial decisions. The information and tips provided on this website are based on our analysts' own insights and experiences. They are therefore for educational purposes only.
.webp)
.webp)
.webp)
.webp)
